Related Experiment Video

Updated: Jun 13, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.6K

Targeting the EphA2 pathway: could it be the way for bone sarcomas?

Giorgia Giordano1,2, Cristina Tucciarello1,3, Alessandra Merlini2

  • 1Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo, TO, Italy.

Cell Communication and Signaling : CCS
|September 9, 2024
PubMed

Insights

Tyrosine kinase receptor Ephrin Type-A Receptor 2 (EphA2) is overexpressed in bone sarcomas, driving tumor progression. Targeting EphA2 offers new precision medicine strategies for treating these aggressive cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Bone sarcomas are aggressive cancers originating from mesenchymal cells.
  • Current treatments for advanced, unresectable bone sarcomas are limited.
  • Understanding molecular drivers is key for developing novel therapies.

Purpose of the Study:

  • To review the role of Ephrin Type-A Receptor 2 (EphA2) in bone sarcoma development and metastasis.
  • To explore strategies for targeting EphA2 in precision medicine for bone sarcomas.
  • To focus on EphA2's relevance in osteosarcoma, chondrosarcoma, and Ewing sarcoma.

Main Methods:

  • Literature review synthesizing existing research on EphA2.
  • Analysis of molecular, genetic, biochemical, and pharmacological data related to EphA2.
  • Focus on EphA2's functions in tumor progression, metastasis, self-renewal, and chemoresistance.

Main Results:

  • EphA2 is overexpressed in bone sarcomas and acts as a key oncofetal protein.
  • EphA2 signaling pathways are implicated in tumor metastasis, self-renewal, and chemoresistance.
  • Various approaches exist to target EphA2 for therapeutic or diagnostic purposes.

Conclusions:

  • EphA2 represents a promising target for developing innovative treatments for bone sarcomas.
  • Targeting EphA2 can potentially overcome limitations in current therapeutic strategies.
  • Further research into EphA2-based interventions is warranted for osteosarcoma, chondrosarcoma, and Ewing sarcoma.
Keywords:
Bone sarcomasDrug deliveryEphA2ImmunotherapyTargeted therapy

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.2K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K